My name is Paul Hopper, and I'm the Executive Chairman of Chimeric Therapeutics. Before we get started today, I'd like to acknowledge the lands of the Gadigal people of the Eora Nation, from which I'm hosting the meeting today, and we pay our respects to elders past and present. We also acknowledge the traditional custodians of the various lands on which you are joining us today, and any Aboriginal and Torres Strait Islander people participating in the meeting. The meeting today is being held online and hosted from 62 Lygon Street in Victoria. This allows shareholders, proxy holders, and guests to attend the meeting either virtually and/or in person, and everyone can watch a live webcast of the meeting. In addition, shareholders and proxy holders, of course, can ask questions and submit their vote
Going to questions, during today's meeting, shareholders or appointed representatives have the opportunity to ask questions or make comments, either personally or by raising voting and non-voting cards, or if you're coming to us remotely using the Lumi platform that you've logged into today. On the platform, the questions will be moderated and may be amalgamated where there are multiple questions on the same topic. What we'll do is have you restrict your questions to the resolutions at hand, and any general questions we can answer at the end of today's meeting. For those of you who are online, to ask a question, you click on the messaging icon at the top of the screen, type your question, and then click the arrow to submit your question. You will receive confirmation that your question has been sent after you click on the send arrow.
That function is now open, so it would be helpful if you could submit questions as early as possible. When you submit your question, please identify which resolution it relates to, or if it does not relate to any resolution, please indicate it is a general question. Just to confirm, each resolution, if there are any questions, will only take questions relating to the resolution. General questions will take place at the end. You can submit questions from now on, but they won't be answered until a relevant time. Finally, due to time constraints, we might run out of time to answer all of your questions. If this does happen, we'll answer them in due course via email or by posting responses on our website. Today voting will be conducted by way of a poll on all items of the business.
For those of you who are attending in person, they're in the room and entitled to vote. Please pass your signed voting card to a boardroom representative at the conclusion of the meeting. The voting is now open on the Lumi online portal. By clicking the bar chat icon, each of the resolutions and the voting options will appear on your screen, and you may vote for a motion, against a motion, or you may simply choose to abstain, and you can change your vote at any time before the poll closes. The poll will remain open until the conclusion of the meeting. If you need to go early, you can cast your vote now. At the end of the meeting, voting will be collated to include all proxy votes and those cast at today's meeting, and the final results will be announced on the ASX later today.
Before we get into the resolutions, I'd like to introduce my fellow Directors, Executive Management, and Joint Company Secretaries. I've got Mr. Eric Sullivan, Non-Executive Director in the U.S., Philip Hains, Non-Executive Director, CFO and Joint Secretary, Nathan Young, Joint Secretary, and Rebecca McQualter, the CEO, of course. I have apologies from Dr. Leslie Russell in Florida and Professor Miles Prince in Melbourne. Could you all put yourselves on mute unless you're speaking? What I'd like to do now is, before we begin the formal part of the meeting, I'll have Rebecca make a brief presentation. If any questions arise from that presentation, we'll add some at the end. After her presentation, we'll start the formal part of the business. With that, I'll ask Rebecca to come forward and present to shareholders. Rebecca.
Thank you so much, Paul. Good morning, everyone. I just want to take you through a really quick summary. Next slide, please. This is our disclaimer. Can you keep going FY 2025 in summary FY 2025 was my first full year at the helm, and I'm really delighted to say that we raised AUD 16.6 million across the year, which includes AUD 5.6 million from the U.S. Family Office. After today, I'm really delighted that the Lynde facility will be paid out in full, and it's really great to have that facility closed now. Throughout FY 2025, as I've mentioned previously, we've made significant headcount and cost reductions, and I'm really pleased at how the business is running. I'd like to thank everyone here in the room today for their support, and also our current shareholders and our new shareholders after today.
For our clinical development, I'll give you an update on two of our programs, and we're still working on chlorotoxin and figuring out how we can bring that technology home. For CHM CDH17, we've commenced the trial late last year. We've treated five patients. We've completed dose level one with our best result being one patient that still has stable disease after six months. We've started dose level two, and we've had eight out of eight successful manufacturing runs. As I've mentioned previously, manufacturing runs in cell therapy are a big deal. This is a big milestone for us. Moving on to CHM Core NK. This is our off-the-shelf NK product. The dose finding was completed late last year at MD Anderson Cancer Center, and we've now moved into a frontline setting for the advent AML study.
As announced in May, we had two complete responses with incomplete blood count recovery. The neutrophils were still a little bit low, but there's no sign of leukemia in those patients, which is really great. Next slide, please. Moving into CHM CDH17 in a tiny bit more detail. Next slide. This is dose level one, the summary at dose level one. As I mentioned, our best result is still patient number three with colorectal cancer, who still has stable disease out past 150 days, which is great to see. From the translational data that we also announced in early June, we can see CAR T positive cells in her peripheral blood well out past 150 days, which means that the cells are hanging around and doing their surveillance. We're really impressed with how the cells are performing. Next slide, please.
As we move into dose level two now, patient five was treated. She's passed the DLT, which is the dose-limiting toxicity window of 28 days. We're still waiting for her scan to come through, but we're cleared now to dose patient six and seven in the coming weeks when they're ready to be dosed. We're moving at a great pace. Everyone's been manufactured for, and we're just waiting for them to be treated. I hope to share some results shortly on the CHM CDH17 trial. Next slide, please. Just quickly, in more detail about CHM Core NK, the results that we announced in May. Next slide, please. Two out of three patients have had a complete response, which is a really great start to this frontline portion of the study.
I did have my call with MD Anderson this morning, and they're progressing through recruitment for the next three patients, and we'll hopefully have some more updates in the future. With that, that concludes my very brief presentation today. Should you have any questions, please pop them into the chat. Thank you, Paul.
All right, thank you, Rebecca. Let's now go to quorum and proxies. I'm advised that the notices of meetings have been properly dispatched and that a quorum of members is present. Accordingly, I now call the meeting to order. I also propose that in the interest of efficiency, the notice of meeting be taken as read and that we now move to the ordinary business of the meeting. The proxies received are held by the company's share registry, and I advise that I will vote all undirected proxies in my control in favor of each resolution. Turning now to the resolutions, the resolutions today are ordinary resolutions, and they require 50% or more votes in favor for the resolution to pass. Let's now actually get into the formal part of the resolutions, and that's resolution one, which is the ratification of prior issue of first tranche placement shares.
This is to ratify the issuance of 164.3 million first tranche placement shares to sophisticated and professional investors. The proxy results are shown on the screen and will be determined by Paul at the conclusion of the meeting. As you can see, there are 427.7 million proxies lodged, of which 86% are in favor of the resolution and 14% against. It would appear that that resolution has been overwhelmingly carried, but the final results will be released to the ASX today. I ask either Philip or Nathan, are there any questions relating to this resolution?
There are no questions in relation to this resolution, Mr. Chin.
Thank you. Let us now go to resolution two, which is the approval to issue second tranche placement shares. The purpose of this resolution is for shareholders to approve under Listing Rule 7.1 and for all other purposes, the issue and allotment of up to 1.485 billion second tranche placement shares to placement subscribers on the terms set out in the notice of meeting. The proxy results are now displayed on the screen and will be determined by Paul at the conclusion of the meeting. As you can see there, there were 427.7 million proxy votes lodged, of which 85% were in favor, 15% against. It would appear that the resolution is overwhelmingly carried. The results will be announced to the ASX later today. Philip, are there any questions relating to this resolution?
No, there are no questions in relation to resolutions to Chairman.
Thank you. Let's move now to resolution three, which is the approval to issue attaching options. The purpose of this is for shareholders to approve under Listing Rule 7.1 and for all other purposes, the issue of up to 1.65 billion attaching options. The proxy results are displayed on the screen. There were 427.7 million proxy votes lodged, of which 79% were in favor and 21% against. It would appear this has been carried, but the final results will be announced to the stock exchange later today. Philip, do we have any questions relating to resolution three?
No, there are no questions in relation to resolutions, Chairman.
Thank you. Let's move now to resolution four, which is the approval to issue advisor options. The purpose of this resolution is for shareholders to approve under Listing Rule 7.1 and for all other purposes, the issue of up to 25 million advisor options to PAC Partners and Taylor Collison on account of professional services provided to the company. The results are shown on the screen, and you can see there were 428.4 million proxy votes lodged, of which 79% were in favor, 21% against. It would appear that this resolution has been carried, but we will announce the final results to the ASX at the end of the day. Philip, do we have any questions on resolution four?
No, there are no questions in relation to resolutions, Chair.
Thank you. Let's move now to resolution 5A and 5B, which is the approval to issue shares and options to Lynde. That's the facility that Rebecca referred to be paid out. We're going to consider both these resolutions at the same time. The purpose of 5A is for shareholders to approve under Listing Rule 7.1 and for all other purposes, the issue of 141.25 million shares to Lynde. The purpose of resolution 5B is for shareholders to approve under Listing Rule 7.1 and for all other purposes, the issue of up to 141.25 million attaching options to Lynde. The proxy results are shown on the screen. There are, in both cases, 428.4 million shares lodged, of which 73% were in favor, 27% against. It would appear the resolution is carried, but the final results will be announced later this afternoon. Philip, do we have any questions relating to this resolution?
No, there are no questions in relation to this resolution, Mr. Chair.
All right, I think that concludes the formal part of the meeting. Let us go into Q&A, and it would appear, if I'm reading it correctly, Philip, that there are no Q&A that's come online. Is that correct?
Yes, that's correct, Mr. Chair. No, no questions from the floor in the room here or online.
Okay, I believe that being the case, this concludes the business of the meeting. The voting system will close at the end of the meeting, and the result of the resolutions will be released to the ASX later today. Please immediately cast any remaining votes now. I thank you for your attendance, and I declare the meeting closed.
Thank you very much.
Thanks.